SAB Biotherapeutics (SABS) Net Margin (2021 - 2024)
SAB Biotherapeutics' (SABS) quarterly Net Margin came in at 9934.52% in Q4 2024, down 244077.0% YoY from N/an in Q1 2024, and down 256.37% on a QoQ basis from 2787.69% in Q2 2024.
Powered by 
Analysis
SAB Biotherapeutics (SABS) Net Margin (2021 - 2024) Analysis & Trends
SAB Biotherapeutics (SABS) has 4 years of Net Margin data on file, last reported at 9934.52% in Q4 2024.
- Quarterly Net Margin fell 244077.0% year-over-year to 9934.52% in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 2579.03% (down 69453.0% YoY) and the FY2024 annual result came in at 2579.03%, down 69453.0% from the prior year.
- Net Margin eased to 9934.52% in Q4 2024, from 2787.69% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 8.35% in Q1 2022 to a low of 9934.52% in Q4 2024.
- A 4-year average of 2082.04% and a median of 364.42% in 2022 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2023 — Net Margin tumbled 797092 bps — and 2024, when it surged 525843 bps.
- Tracing SABS's Net Margin over 4 years: stood at 104.46% in 2021, then sank by 249 bps to 364.42% in 2022, then sank by 1956 bps to 7493.75% in 2023, then tumbled by 33 bps to 9934.52% in 2024.
- The last three Net Margin figures came in at 9934.52% (Q4 2024), 2787.69% (Q2 2024), and 532.06% (Q1 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -539.31% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.90% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 12.74% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -3.12% |
| 10 | SAB Biotherapeutics | 296.68 Mn | 296.68 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | -9,934.52% |
| Jun 30, 2024 | -2,787.69% |
| Mar 31, 2024 | -532.06% |
| Dec 31, 2023 | -7,493.75% |
| Sep 30, 2023 | -402.59% |
| Jun 30, 2023 | -8,046.13% |
| Mar 31, 2023 | -1,265.50% |
| Dec 31, 2022 | -364.42% |
| Sep 30, 2022 | -197.12% |
| Jun 30, 2022 | -75.21% |
| Mar 31, 2022 | 8.35% |
| Dec 31, 2021 | -104.46% |
| Sep 30, 2021 | -27.66% |
| Jun 30, 2021 | -16.15% |
| Mar 31, 2021 | 8.33% |